Yep, Jennifer is correct. The MANF patents alone make this company worth a helluva lot more than $6 Million. Amgen spent over $300 Million on GDNF and MANF has shown far better results than GDNF and it has potential applications in Alzheimers, TBI, and a host of other diseases / injuries that have multi billion dollar market potentials.
Remember what the co-founder of AMGN said:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."